Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Lise Davenne"'
Autor:
Michael R. Paillasse, James Garner, Michael Fitzgerald, Lise Davenne, Pierre-Benoit Ancey, celine Poussereau-Pomie, Michael Esquerre, Gaelle Badet, Joel Tuyaret, Marie Mandron, Philippe Rochaix, Maha Ayyoub, Clara Maria Scarlata, Christine Ménétrier-Caux, Chrsitophe CAUX, Philippe Cassier, Jean-Pierre Delord, Carlos Gomez Roca, Pierre Fons
Publikováno v:
Cancer Research. 82:3203-3203
Introduction: EVT801 is a highly selective small molecule inhibitor of VEGFR3 and acts by inhibiting lymphangiogenesis and tumor angiogenesis in and around the tumor. It has shown compelling activity in a wide range of cancer models and is well-toler
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ad6e685d7e1bfe24767d84b1ebbaadae
https://doi.org/10.1158/1538-7445.am2022-3203
https://doi.org/10.1158/1538-7445.am2022-3203
Autor:
Carlos Gomez roca, Philippe Cassier, Marie Mandron, Myriam Estrabaut, Nathalie Delesque-Touchard, Adam C. Smith, Amy Klawitter, Leesa Gentry, Pierre Fons, Michael R. Paillasse, Lise Davenne, Michael Fitzgerald, James Garner, Jean-Pierre Delord
Publikováno v:
Cancer Research. 82:CT206-CT206
Introduction: EVT801 is a highly selective, orally available VEGFR3 inhibitor that strongly inhibits angiogenesis without inducing hypoxia, considered one of the main causes of cancer-associated immunosuppression. EVT801 has shown compelling single a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6fae4f0d1e0743ec14cffdced09d61f9
https://doi.org/10.1158/1538-7445.am2022-ct206
https://doi.org/10.1158/1538-7445.am2022-ct206
Autor:
Olivier Cuvillier, Marie-Bernadette Delisle, Corinne Bousquet, Julie Guillermet-Guibert, Nathalie Saint-Laurent, Lise Davenne, Dimitri Pchejetski, Leyre Brizuela, Christiane Susini, Céline Guilbeau-Frugier
Publikováno v:
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, 2009, 8 (4), pp.809-20. ⟨10.1158/1535-7163.MCT-08-1096⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2009, 8 (4), pp.809-20. ⟨10.1158/1535-7163.MCT-08-1096⟩
Molecular Cancer Therapeutics, 2009, 8 (4), pp.809-20. ⟨10.1158/1535-7163.MCT-08-1096⟩
Molecular Cancer Therapeutics, American Association for Cancer Research, 2009, 8 (4), pp.809-20. ⟨10.1158/1535-7163.MCT-08-1096⟩
Defeating pancreatic cancer resistance to the chemotherapeutic drug gemcitabine remains a challenge to treat this deadly cancer. Targeting the sphingolipid metabolism for improving tumor chemosensitivity has recently emerged as a promising strategy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::faf735aa25fd9b438c1451ff93619dd9
https://www.hal.inserm.fr/inserm-00409953
https://www.hal.inserm.fr/inserm-00409953
